Food deprivation decreases mRMA and activity of the rat dopamine transporter

Neuroendocrinology

Volumn 68, Issue 1, 1998, Pages 11-20

  Patterson, Terrell Ann ^a   Brot, Michelle D ^c   Zavosh, Aryana ^a   Schenk, James O ^d   Szot, Patricia ^b,c   Figlewicz, Dianne P ^a,c   Figlewicz Lattermann, Dianne ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Catecholamines; Dopamine transporter; Food deprivation; In situ hybridization; Insulin

Indexed keywords

DOPAMINE TRANSPORTER; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FOOD DEPRIVATION; IN SITU HYBRIDIZATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; POTENTIOMETRY; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TEGMENTUM;

ANIMALS; CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FOOD DEPRIVATION; INSULIN; KINETICS; MALE; MAZINDOL; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NUCLEUS ACCUMBENS; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 0031806149     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054345     Document Type: Article

References (54)

1. Strange PG: New insights into dopamine receptors in the central nervous system. Neurochem Int 1993;22:223-236.
2. Creese I, Hurt DR, Snyder SH: Biochemical actions of neuroleptic drugs: Focus on the dopamine receptor; in Iversen LL, Iversen SD, Snyder SH (eds): Handbook of Pharmacology. New York, Plenum Press, 1978, vol 10, pp 37-90.
3. Baldessarini RJ, Tarsy D: Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Annu Rev Neurosci 1980;3: 23-41.
4. Baldessarini RJ, Tarsy D: Pathophysiological basis of tardive dyskinesia. Adv Biochem Psychopharm 1980;24:451-455.
5. Kuhar MJ, Ritz MC, Boja JW: The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14:299-302.
6. Koob GF: Drugs of abuse: anatomy, pharmacology, and function of reward pathways. Trends Pharm Sci 1992;13:177-184.
7. Hitri A, Hurd YL, Wyatt RJ, Deutsch SI: Molecular, functional and biochemical characteristics of the dopamine transporter: Regional differences and clinical relevance. Clin Neuropharm 1994;17:1-22.
8. Amara SG, Kuhar MJ: Neurotransmitter transporters: Recent progress. Annu Rev Neurosci 1993;16:73-93.
9. Giros G, Jaber M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379: 606-612.
10. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG: Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter. J Neurochem 1997;69:1322-1325.
11. Bannon MJ, Granneman JG, Kapatos G: The dopamine transporter: Potential involvement in neuropsychiatric disorders; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven, 1995, pp 179-188.
12. Povlock SL, Amara SG: The structure and function of norepinephrine, dopamine and serotonin transporters; in Reith MEA (ed): Neurotransmitter Transporters. Totowa, Humana, 1997, pp 1-28.
13. Chu PC, Lin MT, Shian LR, Leu SY: Alterations in physiologic functions and in brain monoamine content in streptozotocin-diabetic rats. Diabetes 1986;35:481-485.
14. Leedom LJ, Meehan WP: The psychoneuroendocrinology of diabetes mellitus in rodents. Psychoneuroendocrinology 1989;14:275-294.
15. Shimomura Y, Shimizu H, Takahashi M, Uehara Y, Kobayashi I, Kobayashi S: Ambulatory activity and dopamine turnover in streptozotocin-induced diabetic rats. Exp Clin Endocrinol 1990;95:385-388.
16. Bellush LL, Reid SG: Altered behavior and neurochemistry during short term insulin withdrawal in streptozotocin-diabetic rats. Diabetes 1991;40:217-222.
17. Sandy k R: The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 1993;69:125-130.
18. Heaton JP, Varrin SJ: Effects of streptozotocin-induced diabetes on dopaminergic functioning in the rat: Analysis of yawning behavior. Pharm Biochem Behav 1993;44:601-604.
19. Figlewicz DP, Brot MD, McCall AL, Szot P: Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: A molecular study. Brain Res 1996;736: 54-60.
20. Figlewicz DP, Szot P, Chavez M, Woods SC, Veith RC: Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res 1994;644:331-334.
21. Bell SM, Steward RB, Thompson SC, Meisch RA: Food-deprivation increases cocaine-induced conditioned place preference and locomotor activity in rats. Psychopharmacology 1997;131:1-8.
22. Carroll ME, Meisch RA: Increased drug-reinforced behavior due to food deprivation; in Thompson T, Dews PB, Barrett JE (eds): Advances in Behavioral Pharmacology. New York, Academic Press, 1984, pp 47-88.
23. Morgan DR, Lazarow A: Immunoassay of insulin: Two-antibody system. Diabetes 1963; 12: 115-126.
24. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 2. Orlando, Academic Press, 1986.
25. 125I]RTI-121. Synapse 1995;21:364-372.
26. Meiergerd SM, Schenk JO: Measurement of time-resolved kinetics of biogenic amine release and transporter activity by rotating disk electrode voltammetry in vitro; in Boulton AA, Baker GB, Adams RN (eds): Neuromethods. Voltammetric Methods in Brain Systems. Totowa, Humana, 1995, vol 27, pp 305-337.
27. Schenk JO, Patterson TA, McElvain JS: Rotating disk voltammetric measurements in neurobiology and neuropharmacology. Trends Anal Chem 1990;9:325-330.
28. McElvain JS, Schenk JO: Blockade of dopamine autoreceptors by haloperidol and the apparent dynamics of potassium-stimulated endogenous release of dopamine from and reuptake into striatal suspensions in the rat. Neuropharmacology 1992;31:649-659.
29. Meiergerd SM, Hooks SM, Schenk JO: The striatal transporter for dopamine in the rat may be kinetically up-regulated following 3 weeks of withdrawal from cocaine self-administration. J Neurochem 1994;63:1277-1281.
30. 2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 1993;61:764-767.
31. Havilcek LL, Crain TK: Practical Statistics for the Physical Sciences. Washington, American Chemical Society, 1988.
32. Stein WD: Transport and Diffusion Across Cell Membranes. San Diego, Academic Press, 1986.
33. Stein WD: Kinetics of transport: Analyzing, testing, and characterizing models using kinetic approaches. Adv Enzymol 1989;171:23-62.
34. Pifl C, Giros B, Caron MG: Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 1993;13:4246-4253.
35. Burnette WB, Danna Bailey M, Kokoy S, Blakely RD, Trowbridge CG, Justice JB Jr: Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal Chem 1996;68:2932-2938.
36. Ramamoorthy S, Cool DR, Mahesh VB, Leibach FH, Melikian HE, Blakely RD, Ganapathy V: Regulation of the human serotonin transporter. Cholera toxin-induced stimulation of serotonin uptake in human placental choriocarcinoma cells is accompanied by increased serotonin transporter mRNA levels and serotonin transporter-specific ligand binding. J Biol Chem 1993;268:21626-21631.
37. Liu F, McConkey F, Man HY, Lee FJS, Levey AI, Wang YT, PristupaZB, Niznik HB: Second messenger mediated translocation of the human dopamine transporter. Soc Neurosci Abstr 1997;23:692.
38. Corey JL, Davidson N, Lester HA, Brecha N, Quick MW: Protein kinase C modulates the activity of a cloned γ-aminobutyric acid transporter expressed in Xenopus oocytes via regulated subcellular redistribution of the transporter. J Biol Chem 1994;269:14759-14767.
39. Hanson ES, Levin N, Dallman MF: Elevated corticosterone is not required for the rapid induction of neuropeptide Y gene expression by an overnight fast. Endocrinology 1997;138: 1041-1047.
40. Patterson TA, Figlewicz Lattemann D: Acute corticosterone incubation in vitro inhibits the function of the dopamine transporter in nucleus accumbens but not the striatum of the rat brain: An in vitro voltammetric study. Soc Neurosci Abst 1997;23:693.
41. Fleckenstein AE, Pogun S, Carroll FI, Kuhar MJ: Recovery of dopamine transporter binding and function after intrastriatal administration of the irreversible inhibitor RTI-76 [3 B-(3p-chlorophenyl) tropan-2 beta-carboxylic acid p-isothiocyanatophenylethyl ester hydrochloride]. J Pharm Exp Ther 1996;279:200-206.
42. Silvia CP, Jaber M, King GR, Ellinwood EH, Caron MG: Cocaine and amphetamine elicit differential effects in rats with a unilateral injection of dopamine transporter antisense oligodeoxynucleotides. Neuroscience 1997;76: 737-747.
43. Zhou D, Huether G, Wiltfang J, Hajak G, Ruther E: Serotonin transporters in the rat frontal cortex: Lack of circadian rhythmicity but down-regulation by food restriction. J Neurochem 1996;67:656-661.
44. Cheatham B, Kahn CR: Insulin action and the insulin signaling network. Endo Rev 1995;16: 117-142.
45. Simon JR, Bare DJ, Ghetti B, Richter JA: A possible role for tyrosine kinases in the regulation of the neuronal dopamine transporter in mouse striatum. Neurosci Lett 1997;224:201-205.
46. max. J Neurochem 1997;68:225-232.
47. Unger J, McNeill TH, Moxley RT, White M, Moss A, Livingston JN: Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neurosciences 1989;31:143-157.
48. Werther GA, Hogg A, Oldfield BJ, McKinley MJ, Figdor R, Allen AM, Mendelsohn FAO: Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 1987;121:1562-1570.
49. Moroo I, Yamada T, Makino H, Tooyama I, McGeer PL, McGeer EG: Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol Berlin 1994;87:343-348.
50. Takahashi M, Yamada T, Tooyama I, Kimura H, Yamamoto T, Okada H: Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci Lett 1996;204:201-204.
51. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F: Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 1994;35: 494-498.
52. Thompson TL, Moss RL: Estrogen regulation of dopamine release in the nucleus accumbens: Genomic- and nongenomic-mediated effects. J Neurochem 1994;62:1750-1756.
53. Fumagalli F, Jones SR, Caron MG, Seidler FJ, Slotkin TA: Expression of mRNA coding for the serotonin transporter in aged vs. young rat brain: Differential effects of glucocorticoids. Brain Res 1996;719:225-228.
54. Miller KJ, Hoffman BJ: Adenosine AS receptors regulate serotonin transport via nitric oxide and cGMP. J Biol Chem 1994;44:27351-27356.